At the news
? MIXEDIMPACT 5/10 8-K filed May 13, 2026 at 08:00 ET
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R&D spending. Cash and investments stood at $383.5M following a $147.9M ATM raise, extending runway into 2H 2028. Pipeline advancements include first patient dosed in potentially registrational SURF303 study and dose escalation cleared in BEACH301.
- Q1 2026 net loss per share -$0.64 vs -$0.47 in Q1 2025
- Cash and marketable securities of $383.5M; runway into 2H 2028
- Received $147.9M net proceeds from ATM offering (4,690,532 shares)
- First patient dosed in Phase 2a/b SURF303 study for LG-UTUC; initial results 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access